Pharmacokinetic drug‐drug interaction between erlotinib and paracetamol: A potential risk for clinical practice

Background: Erlotinib is a tyrosine kinase inhibitor available for the treatment of non‐small cell lung cancer. Paracetamol is an analgesic agent, commonly used in cancer patients. Because these drugs are often co‐administered, there is an increasing issue of interaction between them. Objective: The aim of the study was to investigate the effect of paracetamol on the pharmacokinetic parameters of erlotinib, as well as the influence of erlotinib on the pharmacokinetics of paracetamol. Methods: The rabbits were divided into three groups: the rabbits receiving erlotinib (IER), the group receiving paracetamol (IIPR), and the rabbits receiving erlotinib + paracetamol (IIIER + PR). A single dose of erlotinib was administered orally (25 mg) and was administered intravenously (35 mg/kg). Plasma concentrations of erlotinib, its metabolite (OSI420), paracetamol and its metabolites – glucuronide and sulphate were measured with the validated method. Results: During paracetamol co‐administration we observed increased erlotinib maximum concentration (Cmax) and area under the plasma concentration‐time curve from time zero to infinity (AUC0‐∞) by 87.7% and 31.1%, respectively. In turn, erlotinib lead to decreased paracetamol AUC0‐∞ by 35.5% and Cmax by 18.9%. The mean values of paracetamol glucuronide/paracetamol ratios for Cmax were 32.2% higher, whereas paracetamol sulphate/paracetamol ratios for Cmax and AUC0‐∞ were 37.1% and 57.1% lower in the IIPR group, when compared to the IIIER + PR group. Conclusions: Paracetamol had significant effect on the enhanced plasma exposure of erlotinib. Additionally, erlotinib contributed to the lower concentrations of paracetamol. Decreased glucuronidation and increased sulphation of paracetamol after co‐administration of erlotinib were also observed.

[1]  V. Bourgarel-Rey,et al.  Metabolism of carbamazepine by CYP3A6: a model for in vitro drug interactions studies. , 1999, Life sciences.

[2]  J. Owczarek,et al.  Influence of simvastatin at high dose and nifedipine on hemodynamic parameters in rabbits. , 2006, Pharmacological reports : PR.

[3]  R. Rosell,et al.  Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors , 2016, Investigational New Drugs.

[4]  Yan-Yan Zhang,et al.  Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib , 2011, Acta Pharmacologica Sinica.

[5]  Hau D. Le,et al.  Effect of sunitinib on functional reproductive outcome in a rabbit model. , 2012, Fertility and sterility.

[6]  Ravindrababu Pingili,et al.  Systemic exposure of Paracetamol (acetaminophen) was enhanced by quercetin and chrysin co-administration in Wistar rats and in vitro model: risk of liver toxicity , 2015, Drug development and industrial pharmacy.

[7]  G. Chmielewski,et al.  Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. , 2009, Birth defects research. Part B, Developmental and reproductive toxicology.

[8]  C. Stewart,et al.  Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation , 2010, Clinical Cancer Research.

[9]  Irena Manov,et al.  Involvement of the multidrug resistance P-glycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells. , 2006, Basic & clinical pharmacology & toxicology.

[10]  K. Allegaert,et al.  Covariates of intravenous paracetamol pharmacokinetics in adults , 2014, BMC Anesthesiology.

[11]  M. Ratain,et al.  Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. , 2011, British journal of clinical pharmacology.

[12]  P. Schaiquevich,et al.  Evaluation of acetaminophen P-glycoprotein-mediated salivary secretion by rat submandibular glands. , 2004, Archives of oral biology.

[13]  Bin Zhang,et al.  Chronopharmacokinetics of Erlotinib and Circadian Rhythms of Related Metabolic Enzymes in Lewis Tumor-Bearing Mice , 2015, European Journal of Drug Metabolism and Pharmacokinetics.

[14]  M. Hidalgo,et al.  Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes , 2007, Clinical Cancer Research.

[15]  P. Zimmerman,et al.  Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen , 2005, Clinical Cancer Research.

[16]  J. N. van den Anker,et al.  Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen , 2016, Clinical Pharmacokinetics.

[17]  J. Beijnen,et al.  Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy. , 2015, Clinical lung cancer.

[18]  Bienert Agnieszka,et al.  Pharmacokinetics and ocular disposition of paracetamol and paracetamol glucuronide in rabbits with diabetes mellitus induced by alloxan , 2012 .

[19]  J. Schellens,et al.  Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice , 2008, Molecular Cancer Therapeutics.

[20]  M. Ratain,et al.  Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-Glucuronosyltransferases , 2010, Drug Metabolism and Disposition.

[21]  M. Djamgoz,et al.  Management of cancer pain: 1. Wider implications of orthodox analgesics , 2014, International journal of general medicine.

[22]  J. Bartlett,et al.  Product information , 2001, Transplantation.

[23]  R. Plummer,et al.  Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer , 2014, Anti-cancer drugs.

[24]  K. Syrigos,et al.  Pain and Anxiety versus Sense of Family Support in Lung Cancer Patients , 2014, Pain research and treatment.

[25]  A. G. Blazquez,et al.  Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line. , 2011, Biochemical pharmacology.

[26]  M. Shahid,et al.  A comparative study of intravenous paracetamol and intravenous tramadol for postoperative analgesia in laparotomies , 2015, Anesthesia, essays and researches.

[27]  A. Novak,et al.  Acetaminophen inhibits intestinal p-glycoprotein transport activity. , 2013, Journal of pharmaceutical sciences.

[28]  M. Ratain,et al.  The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. , 2010, European journal of cancer.

[29]  Z. Bősze,et al.  Application of rabbits in biomedical research: A review , 2010 .

[30]  C. Dittrich,et al.  Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels , 2013, Case Reports in Oncology.

[31]  T. Vanderah,et al.  Acetaminophen Modulates P-Glycoprotein Functional Expression at the Blood-Brain Barrier by a Constitutive Androstane Receptor–Dependent Mechanism , 2013, Molecular Pharmacology.

[32]  K. Ramchandran,et al.  Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer , 2016, Current Treatment Options in Oncology.

[33]  S. Ohdo,et al.  Circadian Modulation in the Intestinal Absorption of P-Glycoprotein Substrates in Monkeys , 2015, Molecular Pharmacology.

[34]  S. Su,et al.  Inhibition of the intestinal digoxin absorption and exsorption by quinidine. , 1996, Drug Metabolism And Disposition.

[35]  Jun-shik Choi,et al.  Effect of naringin pretreatment on bioavailability of verapamil in rabbits , 2006, Archives of pharmacal research.

[36]  Asako Nishimura,et al.  Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats. , 2003, Biological & pharmaceutical bulletin.

[37]  S. Marciano,et al.  Imatinib-induced fatal acute liver failure. , 2007, World journal of gastroenterology.

[38]  B. Lum,et al.  Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals , 2008, Anti-cancer drugs.

[39]  A. Smith,et al.  CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit. , 2001, Biopharmaceutics & drug disposition.

[40]  B. Lum,et al.  Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects , 2006, Journal of clinical pharmacology.

[41]  Jun-shik Choi,et al.  The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits , 2004, The Journal of pharmacy and pharmacology.

[42]  J. Schellens,et al.  Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP , 2012, Investigational New Drugs.

[43]  D. Nehra,et al.  Sunitinib reduces recurrent pelvic adhesions in a rabbit model. , 2012, The Journal of surgical research.

[44]  Hau D. Le,et al.  Sunitinib inhibits postoperative adhesions in a rabbit model. , 2011, Surgery.

[45]  L. J. Brunner,et al.  Simple and rapid assay for acetaminophen and conjugated metabolites in low-volume serum samples. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[46]  B. Laird,et al.  Clinical Management of Pain in Advanced Lung Cancer , 2012, Clinical Medicine Insights. Oncology.

[47]  Jin‐ding Huang,et al.  Inhibition of intestinal P-glycoprotein and effects on etoposide absorption , 2009, Cancer Chemotherapy and Pharmacology.

[48]  I. Higginson,et al.  Pain experienced by lung cancer patients: a review of prevalence, causes and pathophysiology. , 2004, Lung cancer.

[49]  C. Prakash,et al.  METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS , 2006, Drug Metabolism and Disposition.

[50]  A. Prakash,et al.  Effect of esomeprazole on the pharmacokinetics of carbamazepine , 2011, Indian journal of pharmacology.

[51]  O. Höglinger,et al.  Acetaminophen Changes Intestinal Epithelial Cell Membrane Properties, Subsequently Affecting Absorption Processes , 2013, Cellular Physiology and Biochemistry.

[52]  O. Mir,et al.  A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[53]  S. Peters,et al.  Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. , 2014, Cancer treatment reviews.

[54]  M. Perassolo,et al.  Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. , 2004, Biochemical pharmacology.